<DOC>
	<DOCNO>NCT00129376</DOCNO>
	<brief_summary>Treatment consist 4 AC cycle follow 2 weekly docetaxel cycle ( 12 infusion ) . The pathological complete response rate obtain previous study around 12 % . The expected pathological complete response rate study 25 % . With alpha error 0.05 beta error 0.2 , follow SimonÂ´s 2 phase test , 19 patient need initially . With 2 pathological complete response , patient recruitment continue approximately 61 patient recruit . Twelve pathological complete response need confirm study hypothesis .</brief_summary>
	<brief_title>Doxorubicin Cyclophosphamide ( AC ) Followed Weekly Docetaxel Neoadjuvant Treatment Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Written inform consent . Patients breast cancer stage II IIIA , histological diagnosis per truecut open biopsy . Negative extension study , include bilateral mammography , thoracic xray , compute tomography ( CT ) scan abdominal echography bone scintigraphy . Analysis hormone receptor status primary tumour . It highly recommend obtain tumour tissue sample start treatment , definitive surgery . These sample analyse centrally GEICAM . Age &gt; = 18 &lt; = 70 year old . Performance status per Karnofsky index &gt; = 80 . Minimum life expectancy 6 month . Electrocardiogram ( EKG ) 12 week registration study . If abnormality suspect , cardiac function must assess leave ventricular ejection fraction ( LVEF ) . Haematology : neutrophil &gt; = 2.0 x10^9/l ; platelet &gt; = 100 x10^9/l ; hemoglobin &gt; =10 g/dl . Hepatic function : total bilirubin &lt; = 1 x upper normal limit ( UNL ) ; SGOT SGPT &lt; = 2.5 x UNL ; alkaline phosphatase &lt; = 5 x UNL . Renal function : creatinine &lt; = 1.5 x UNL ; creatinine clearance &gt; = 60 ml/min . Patients able comply study requirement . Negative pregnancy test . Adequate contraceptive method study 3 month definitive surgery . Previous systemic therapy breast cancer treatment . Previous treatment anthracyclines taxanes malignancy . Previous radiotherapy breast cancer . Bilateral invasive breast cancer . Pregnant lactating woman . Previous motor sensorial neurotoxicity grade &gt; =2 . Other serious pathology : congestive heart failure angina pectoris ; history myocardial infarction previous year ; uncontrolled hypertension ( HT ) high risk arrhythmia . History neurological psychiatric impairment , preclude patient provide free informed consent . Active infection . Active peptic ulcer ; unstable diabetes mellitus . History previous current malignancy breast cancer , except basal skin carcinoma , cervical situ carcinoma , tumour diagnose treat 10 year , ductal carcinoma situ ( DCIS ) lobular carcinoma situ ( LCIS ) . Chronic treatment corticoid unless treatment start &gt; 6 month registration study , low dos administer . Substitutive hormonal therapy . This treatment must interrupt inclusion study . Concomitant treatment investigational product administration 30 previous day . Males .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Stage II IIIA breast Cancer .</keyword>
	<keyword>Neoadjuvant chemotherapy .</keyword>
	<keyword>Weekly docetaxel .</keyword>
</DOC>